Conduit Pharmaceuticals Inc. Cash Flow Conversion Efficiency
Conduit Pharmaceuticals Inc. cash flow conversion efficiency. Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) has a cash flow conversion efficiency ratio of 0.031x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($42.74 Million) by net assets ($1.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Conduit Pharmaceuticals Inc. (2021–2025)
Cash flow conversion efficiency of Conduit Pharmaceuticals Inc. from 2021 to 2025. This chart illustrates how Conduit Pharmaceuticals Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Conduit Pharmaceuticals Inc. stock price for real-time trading data and today's change.
Conduit Pharmaceuticals Inc. Cash Flow Conversion Ratio Explained
Conduit Pharmaceuticals Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Conduit Pharmaceuticals Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Conduit Pharmaceuticals Inc. ranked by their cash flow conversion efficiency. Also see Conduit Pharmaceuticals Inc. (CDT) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BurgerFi International, Inc.
NASDAQ:BFICQ
|
-0.056x |
|
creditshelf Aktiengesellschaft
F:CSQ
|
-2.968x |
|
TTW Public Company Limited
F:F1P
|
0.055x |
|
Construction JSC 47
VN:C47
|
N/A |
|
Ordinary Fully Paid Deferred Settlement
AU:IMUDA
|
N/A |
|
TOOSLA SA EO-08125
F:W6Q
|
N/A |
|
Taiwan Styrene Monomer Corp
TW:1310
|
-0.031x |
|
CI Com SA
SW:CIE
|
0.020x |
Annual Cash Flow Conversion Efficiency for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Conduit Pharmaceuticals Inc. from 2021 to 2025. Review Conduit Pharmaceuticals Inc. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.26 Billion | $-15.55 Million | -0.012x | -100.86% |
| 2024-12-31 | $-6.79 Million | $-9.68 Million | 1.425x | -91.57% |
| 2023-12-31 | $-457.00K | $-7.72 Million | 16.904x | +7426.11% |
| 2022-12-31 | $-10.09 Million | $-2.27 Million | 0.225x | +100.22% |
| 2021-12-31 | $20.62K | $-2.15 Million | -104.321x | -- |
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more